Edition:
United States

Dare Bioscience Inc (DARE.OQ)

DARE.OQ on NASDAQ Stock Exchange Capital Market

1.38USD
16 Feb 2018
Change (% chg)

$-0.02 (-1.43%)
Prev Close
$1.40
Open
$1.43
Day's High
$1.44
Day's Low
$1.35
Volume
115,989
Avg. Vol
39,285
52-wk High
$35.70
52-wk Low
$1.35

Chart for

About

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide... (more)
No analyst recommendations are available for .

Overall

Beta: 2.63
Market Cap(Mil.): $8.35
Shares Outstanding(Mil.): 6.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Daré Bioscience Announces Effective License, Collaboration Deal For Topical Sildenafil

* DARÉ BIOSCIENCE, INC. ANNOUNCES EFFECTIVE LICENSE AND COLLABORATION AGREEMENT FOR TOPICAL SILDENAFIL FOR FEMALE SEXUAL AROUSAL DISORDER

Feb 15 2018

BRIEF-Dare Bioscience Inc To Raise About $10.25 Mln

* DARÉ BIOSCIENCE, INC. TO RAISE APPROXIMATELY $10.25 MILLION

Feb 13 2018

BRIEF-Daré Bioscience Announces Proposed Public Offering Of Common Stock

* DARÉ BIOSCIENCE, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Feb 13 2018

BRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD

* DARÉ BIOSCIENCE, INC. ENTERS INTO LICENSE AND COLLABORATION AGREEMENT FOR A PRODUCT WITH THE POTENTIAL TO RECEIVE THE FIRST FDA APPROVAL FOR FEMALE SEXUAL AROUSAL DISORDER

Feb 12 2018

BRIEF-Dare Bioscience Enters Into A License Agreement With Strategic Science And Technologies

* DARE BIOSCIENCE INC - ON FEB 11, 2018, CO ENTERED INTO A LICENSE AGREEMENT WITH STRATEGIC SCIENCE AND TECHNOLOGIES-D & STRATEGIC SCIENCE TECHNOLOGIES

Feb 12 2018

BRIEF-Dare Bioscience Says Entered Into Common Stock Sales Agreement

* DARE BIOSCIENCE SAYS ON JANUARY 4, 2018, CO ENTERED INTO COMMON STOCK SALES AGREEMENT - SEC FILING

Jan 04 2018

Earnings vs. Estimates